Neuronal genetic rescue normalizes brain network dynamics in a lysosomal storage disorder despite persistent storage accumulation

Mol Ther. 2022 Jul 6;30(7):2464-2473. doi: 10.1016/j.ymthe.2022.03.025. Epub 2022 Apr 5.

Abstract

Although neurologic symptoms occur in two-thirds of lysosomal storage disorders (LSDs), for most we do not understand the mechanisms underlying brain dysfunction. A major unanswered question is if the pathogenic hallmark of LSDs, storage accumulation, induces functional defects directly or is a disease bystander. Also, for most LSDs we do not know the impact of loss of function in individual cell types. Understanding these critical questions are essential to therapy development. Here, we determine the impact of genetic rescue in distinct cell types on neural circuit dysfunction in CLN3 disease, the most common pediatric dementia and a paradigmatic neurodegenerative LSD. We restored Cln3 expression via AAV-mediated gene delivery and conditional genetic rescue in a CLN3 disease mouse model. Surprisingly, we found that low-level rescue of Cln3 expression in neurons alone normalized clinically relevant electrophysiologic markers of network dysfunction, despite the presence of substantial residual histopathology, in contrast to restoring expression in astrocytes. Thus, loss of CLN3 function in neurons, not storage accumulation, underlies neurologic dysfunction in CLN3 disease. This impliesies that storage clearance may be an inappropriate target for therapy development and an ineffectual biomarker.

Keywords: CLN3 disease; gene therapy; lysosomal storage disease; neuronal dysfunction.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Brain / metabolism
  • Child
  • Humans
  • Lysosomal Storage Diseases* / genetics
  • Lysosomal Storage Diseases* / metabolism
  • Lysosomal Storage Diseases* / therapy
  • Lysosomes / metabolism
  • Membrane Glycoproteins / genetics
  • Mice
  • Molecular Chaperones / genetics
  • Neuronal Ceroid-Lipofuscinoses* / genetics
  • Neuronal Ceroid-Lipofuscinoses* / metabolism
  • Neuronal Ceroid-Lipofuscinoses* / therapy
  • Neurons / metabolism

Substances

  • CLN3 protein, human
  • CLN3 protein, mouse
  • Membrane Glycoproteins
  • Molecular Chaperones